Cyclophosphamide
Showing 26 - 50 of 5,137
Multiple Sclerosis Trial in Saint Petersburg (Fludarabine Phosphate for Injection)
Recruiting
- Multiple Sclerosis
- Fludarabine Phosphate for Injection
-
Saint Petersburg, Russian FederationFirst Pavlov State Medical University of St. Petersburg
Apr 14, 2023
Tofatib Treatment for IgG4-related Disease
Recruiting
- IgG4-related Disease
-
Shanghai, Shanghai, ChinaShanghai Changhai Hospital
Nov 15, 2022
Idiopathic Membranous Nephropathy Trial (Rituximab, Cyclophosphamide)
Not yet recruiting
- Idiopathic Membranous Nephropathy
- Rituximab
- Cyclophosphamide
- (no location specified)
Aug 22, 2022
Pleural Mesothelioma Trial in Toronto (Cyclophosphamide, Fludarabine, Autologous tumor infiltrating lymphocytes (TILs))
Completed
- Pleural Mesothelioma
- Cyclophosphamide
- +3 more
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Jan 8, 2023
TNBC - Triple-Negative Breast Cancer Trial (epirubicin,cyclophosphamide,paclitaxel,Carrelizumab,
Not yet recruiting
- TNBC - Triple-Negative Breast Cancer
- (no location specified)
May 8, 2023
Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma Trial in Toulouse (Doxorubicin, Cyclophosphamide)
Recruiting
- Advanced Soft-tissue Sarcoma
- Metastatic Soft-tissue Sarcoma
- Doxorubicin
- Cyclophosphamide
-
Toulouse, FranceInstitut Claudius Reagaud-IUCT OncopĂ´le
Oct 6, 2022
Hematological Malignancies Trial (Allogeneic T cell progenitors, cultured ex-vivo)
Not yet recruiting
- Hematological Malignancies
- Allogeneic T cell progenitors, cultured ex-vivo
- (no location specified)
Mar 2, 2023
Patients With MDS, Acute Myeloid Leukemia (AML) Evolving From MDS, and Chronic Myelomonocytic Leukemia (CMML) Trial in Seoul
Active, not recruiting
- Patients With MDS, Acute Myeloid Leukemia (AML) Evolving From MDS, and Chronic Myelomonocytic Leukemia (CMML)
- Cyclophosphamide
-
Seoul, Korea, Republic ofAsan Medical Center, University of Ulsan College of Medicine
Oct 19, 2023
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 Trial in
Not yet recruiting
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- +3 more
- Biospecimen Collection
- +8 more
-
Kansas City, KansasUniversity of Kansas Cancer Center
Nov 27, 2023
Multiple Myeloma, Monoclonal Gammopathy of Renal Significance Trial in United States (Cyclophosphamide, Bortezomib,
Recruiting
- Multiple Myeloma
- Monoclonal Gammopathy of Renal Significance
- Cyclophosphamide
- +3 more
-
Basking Ridge, New Jersey
- +6 more
Oct 16, 2023
Lipodystrophy Acquired, Type1diabetes Trial in Shanghai (Cyclophosphamide)
Recruiting
- Lipodystrophy Acquired
- Type1diabetes
- Cyclophosphamide
-
Shanghai, Shanghai, ChinaChildren's Hospital of Fudan University
Jul 20, 2022
Severe Aplastic Anemia (SAA), Hypo-Plastic Myelodysplastic Syndrome (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) Trial run
Recruiting
- Severe Aplastic Anemia (SAA)
- +2 more
- Cyclophosphamide
- Peripheral Blood Stem Cells
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 28, 2023
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia Trial in Duarte (drug, procedure, other)
Recruiting
- Acute Lymphoblastic Leukemia
- +6 more
- Cyclophosphamide
- +4 more
-
Duarte, CaliforniaCity of Hope Medical Center
Dec 8, 2022
Breast Cancer, Chemo Effect Trial (Epirubicin, Cyclophosphamide, Xihuang Pill, Docetaxel, Epirubicin, Cyclophosphamide,
Not yet recruiting
- Breast Cancer
- Chemotherapy Effect
- Epirubicin, Cyclophosphamide, Xihuang Pill, Docetaxel
- Epirubicin, Cyclophosphamide, Docetaxel
- (no location specified)
Jun 21, 2023
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Leukemia Trial in United States (drug, procedure, other, radiation)
Not yet recruiting
- Acute Lymphoblastic Leukemia
- +10 more
- Busulfan
- +10 more
-
Jacksonville, Florida
- +5 more
Aug 14, 2023
Primary Immune Deficiency Disorder, Immune Deficiency Disease, Bone Marrow Failure Trial in Baltimore (Alemtuzumab, Fludarabine,
Recruiting
- Primary Immune Deficiency Disorder
- +2 more
- Alemtuzumab
- +6 more
-
Baltimore, MarylandJohns Hopkins University
Oct 20, 2022
Hormone Receptor Positive HER-2 Negative Breast Cancer Trial in Shanghai (Docetaxel, Carboplatin, Epirubicin)
Recruiting
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- Docetaxel
- +3 more
-
Shanghai, Shanghai, ChinaBreast cancer institute of Fudan University Cancer Hospital
Jun 12, 2023
Graft-versus-host Disease Trial in New York (Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention)
Active, not recruiting
- Graft-versus-host Disease
- Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention
-
New York, New YorkNYU Langone Health
Aug 5, 2022
Breast Cancer Trial in Chicago (Cyclophosphamide, Methotrexate, Capecitabine)
Recruiting
- Breast Cancer
- Cyclophosphamide
- +2 more
-
Chicago, IllinoisUniversity of Illinois
Oct 18, 2023
Transplant-Related Hematologic Malignancy Trial in Atlanta (Sargramostim, Control Arm)
Recruiting
- Transplant-Related Hematologic Malignancy
- Sargramostim
- Control Arm
-
Atlanta, GeorgiaNorthside Hospital
Oct 19, 2022
Refractory Solid Tumor, Hepatocellular Carcinoma, Malignant Solid Tumor Trial in Memphis (Atezolizumab, Sorafenib, Bevacizumab)
Recruiting
- Refractory Solid Tumor
- +4 more
- Atezolizumab
- +3 more
-
Memphis, TennesseeSt. Jude Children's Research Hospital
Aug 4, 2022
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, MDS Trial in Tucson (Bendamustine, Cyclophosphamide)
Recruiting
- Acute Lymphoblastic Leukemia
- +12 more
- Bendamustine
- Cyclophosphamide
-
Tucson, ArizonaThe University of Arizona Cancer Center
Dec 13, 2022
Ovarian Carcinoma Trial (PEP-DC1, OC-DC, PEP-DC2)
Not yet recruiting
- Ovarian Carcinoma
- PEP-DC1
- +3 more
- (no location specified)
Jan 26, 2023
Metastatic Renal Cell Carcinoma Trial in United Kingdom (Cyclophosphamide 50mg, Pembrolizumab 25 mg/1 ML Intravenous Solution
Recruiting
- Metastatic Renal Cell Carcinoma
- Cyclophosphamide 50mg
- Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA]
-
Cambridge, United Kingdom
- +3 more
Aug 22, 2022